U.S. Artemisinic Acid Market (2025 - 2033)

U.S. Artemisinic Acid Market Summary

The U.S. artemisinic acid market size was estimated at USD 236.6 million in 2024 and is projected to reach USD 367.7 million by 2033, growing at a CAGR of 5.0% from 2025 to 2033. The primary factors driving the U.S. artemisinic acid market include an increase in malaria cases connected to international travel, the rising global resistance to traditional antimalarials, government-supported stockpiling initiatives, and expanded research and development in semi-synthetic production methods.

The rise of Plasmodium falciparum strains resistant to traditional antimalarial drugs in Africa and Southeast Asia is prompting healthcare providers and policymakers to prioritize access to fast-acting artemisinin-based treatments. As resistance patterns evolve, U.S. institutions increase their reliance on advanced artemisinic formulations, driving imports, R&D investment, and stockpiling of effective therapies to ensure readiness against more virulent malaria forms.

Furthermore, biotechnology innovations such as engineered Saccharomyces cerevisiae (yeast)-have enabled more stable and scalable production of artemisinic acid. This reduces reliance on agricultural sources such as Artemisia annua, vulnerable to climate and yield variability. As pharmaceutical companies adopt these methods, the U.S. market benefits from enhanced production reliability and cost-efficiency, supporting broader distribution and emergency preparedness.

Product Insights

Based on product, the antimalarial tablets segment accounted for the largest revenue share of 80.8% and is expected to grow at the fastest CAGR over the forecast period due to rising global travel to malaria-endemic regions. As international travel rebounds post-pandemic, more Americans are visiting malaria-prone countries, increasing the demand for preventive and curative antimalarial medications. During January–December 2023, there were 68 imported malaria cases: San Diego, California (27), Pima, Arizona (18), and El Paso, Texas (23), in comparison to 28 cases in 2022. This increases prescription rates for artemisinin-based combination therapies (ACTs) in travel clinics. Furthermore, rising awareness among travelers and improved diagnostic capabilities have expanded the U.S. artemisinic acid market’s relevance beyond domestic needs.

The antimalarial Injections segment is projected to grow significantly over the forecast period. With increasing global mobility and travel to sub-Saharan Africa, the U.S. reports approximately 2,000 malaria cases annually, the majority caused by P. falciparum and linked to recent travel in Africa. Hospital protocols now emphasize immediate treatment to reduce mortality, driving demand for injectable artesunate.

Key U.S. Artemisinic Acid Company Insights

Some of the key players in the U.S. artemisinic acid market include Sanofi, KPC Pharmaceuticals, Inc., Guilin Pharmaceutical Co., Ltd., and others.

• Sanofi, a global biopharmaceutical leader operating across pharmaceuticals, vaccines, and consumer health. Sanofi’s semi-synthetic artemisinin supports antimalarial therapies, underscoring its role in healthcare innovation and global disease management.

U.S. Artemisinic Acid Market